Valneva Receives Marketing Authorization in Europe for the World’s First Chikungunya Vaccine, IXCHIQ®

LabNews Media LLC
2024-07-01
Aktuelles

Saint Herblain (France), July 1, 2024 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that the European Commission (EC) has granted marketing authorization in Europe for Valneva’s single-dose vaccine, IXCHIQ®, for the prevention of disease caused by the chikungunya virus in individuals 18 years of age and older. The…
Valneva Receives Marketing Authorization in Europe for the World’s First Chikungunya Vaccine, IXCHIQ®

LabNews Media LLC

The Editors in Chief of lab-news.de are Marita Vollborn and Vlad Georgescu. They are bestselling authors, science writers and science journalists since 1994.More details about their writing on X-Press Journalistenbüro (https://xpress-journalisten.com).More Info on Wikipedia:About Marita: https://de.wikipedia.org/wiki/Marita_Vollborn About Vlad: https://de.wikipedia.org/wiki/Vlad_Georgescu

Valneva Receives Marketing Authorization in Europe for the World’s First Chikungunya Vaccine, IXCHIQ®

LabNews Media LLC

Stay Connected

Unmatched reporting

Valneva Receives Marketing Authorization in Europe for the World’s First Chikungunya Vaccine, IXCHIQ®

LabNews Media LLC

Ähnliche Beiträge

Neue Epstein-Akten nennen weitere prominente Namen

Explodierende Kosten der Beamtenpensionen im Vergleich zur gesetzlichen Rente

Tödliche Hasenpest: Drei Menschen in Niedersachsen und Bremen infiziert

Stay Connected

Unmatched reporting